Bristol Myers Squibb: Opdivo Plus Yervoy Didn't Meet Primary Endpoint in Cancer Study
29 July 2022 - 9:50PM
Dow Jones News
By Mary de Wet
Bristol Myers Squibb Co. said part of its study of Opdivo plus
Yervoy to treat patients with localized renal cell carcinoma didn't
meet its primary endpoint of disease-free survival.
Part A of the Phase 3 trial was to evaluate using Opdivo in
combination with Yervoy in patients who have undergone surgery to
remove part or all of a kidney and who are at moderate to high risk
of relapse. Part B of the trial will look at using Opdivo alone,
the company said.
Opdivo and Opdivo-based combinations have demonstrated clinical
benefits for several renal cell cancer patient groups, Bristol
Myers said.
"We are disappointed that the final analysis of CheckMate -914
Part A did not show this same benefit for the post-surgical
treatment of patients with localized RCC," said Dr. Dana Walker,
vice president and development program lead of genitourinary
cancers. "Nonetheless, we are dedicated to continuing research and
advancing cancer care for all patients with RCC."
Write to Mary de Wet at mary.dewet@wsj.com
(END) Dow Jones Newswires
July 29, 2022 07:35 ET (11:35 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2024 to May 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From May 2023 to May 2024